Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER(®), RE-COVER™ II, and RE-MEDY™

The direct oral anticoagulants, e.g., dabigatran etexilate (DE), are effective and well tolerated treatments for venous thromboembolism (VTE). Net clinical benefit (NCB) is a useful concept in weighing potential benefits against potential harm of comparator drugs. The NCB of DE vs. warfarin in VTE t...

Descripción completa

Detalles Bibliográficos
Autores principales: Feuring, Martin, Schulman, Sam, Eriksson, Henry, Kakkar, Ajay J., Schellong, Sebastian, Hantel, Stefan, Schueler, Elke, Kreuzer, Jörg, Goldhaber, Samuel Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5375960/
https://www.ncbi.nlm.nih.gov/pubmed/28210989
http://dx.doi.org/10.1007/s11239-017-1479-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5375960/
https://www.ncbi.nlm.nih.gov/pubmed/28210989
http://dx.doi.org/10.1007/s11239-017-1479-z

Ejemplares similares